Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH
"Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes" (Press release)
Our goal is to keep you comfortable and on track
Naunyn-Schmiedeberg's Arch Pharmacol 399 , 1566315675 (2026)
US$ 26.16
US$ 28.98
US$ 20.25
